117 related articles for article (PubMed ID: 35285960)
1. Rab34 plays a critical role as a bidirectional regulator of osteoclastogenesis.
Feng Y; Tran MT; Lu Y; Htike K; Okusha Y; Sogawa C; Eguchi T; Kadowaki T; Sakai E; Tsukuba T; Okamoto K
Cell Biochem Funct; 2022 Apr; 40(3):263-277. PubMed ID: 35285960
[TBL] [Abstract][Full Text] [Related]
2. Rab11A Functions as a Negative Regulator of Osteoclastogenesis through Dictating Lysosome-Induced Proteolysis of c-fms and RANK Surface Receptors.
Okusha Y; Tran MT; Itagaki M; Sogawa C; Eguchi T; Okui T; Kadowaki T; Sakai E; Tsukuba T; Okamoto K
Cells; 2020 Oct; 9(11):. PubMed ID: 33142674
[TBL] [Abstract][Full Text] [Related]
3. The Inhibitory Role of Rab11b in Osteoclastogenesis through Triggering Lysosome-Induced Degradation of c-Fms and RANK Surface Receptors.
Tran MT; Okusha Y; Feng Y; Morimatsu M; Wei P; Sogawa C; Eguchi T; Kadowaki T; Sakai E; Okamura H; Naruse K; Tsukuba T; Okamoto K
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33302495
[TBL] [Abstract][Full Text] [Related]
4. The fungal metabolite (+)-terrein abrogates osteoclast differentiation via suppression of the RANKL signaling pathway through NFATc1.
Nakagawa S; Omori K; Nakayama M; Mandai H; Yamamoto S; Kobayashi H; Sako H; Sakaida K; Yoshimura H; Ishii S; Ibaragi S; Hirai K; Yamashiro K; Yamamoto T; Suga S; Takashiba S
Int Immunopharmacol; 2020 Jun; 83():106429. PubMed ID: 32222639
[TBL] [Abstract][Full Text] [Related]
5. BSP and RANKL induce osteoclastogenesis and bone resorption synergistically.
Valverde P; Tu Q; Chen J
J Bone Miner Res; 2005 Sep; 20(9):1669-79. PubMed ID: 16059638
[TBL] [Abstract][Full Text] [Related]
6. Rab44, a novel large Rab GTPase, negatively regulates osteoclast differentiation by modulating intracellular calcium levels followed by NFATc1 activation.
Yamaguchi Y; Sakai E; Okamoto K; Kajiya H; Okabe K; Naito M; Kadowaki T; Tsukuba T
Cell Mol Life Sci; 2018 Jan; 75(1):33-48. PubMed ID: 28791425
[TBL] [Abstract][Full Text] [Related]
7. Ameloblastin attenuates RANKL-mediated osteoclastogenesis by suppressing activation of nuclear factor of activated T-cell cytoplasmic 1 (NFATc1).
Chaweewannakorn W; Ariyoshi W; Okinaga T; Fujita Y; Maki K; Nishihara T
J Cell Physiol; 2019 Feb; 234(2):1745-1757. PubMed ID: 30105896
[TBL] [Abstract][Full Text] [Related]
8. Oleanolic acid exerts inhibitory effects on the late stage of osteoclastogenesis and prevents bone loss in osteoprotegerin knockout mice.
Zhao D; Shu B; Wang C; Zhao Y; Cheng W; Sha N; Li C; Wang Q; Lu S; Wang Y
J Cell Biochem; 2020 Jan; 121(1):152-164. PubMed ID: 31318102
[TBL] [Abstract][Full Text] [Related]
9. Hispidulin attenuates bone resorption and osteoclastogenesis via the RANKL-induced NF-κB and NFATc1 pathways.
Nepal M; Choi HJ; Choi BY; Yang MS; Chae JI; Li L; Soh Y
Eur J Pharmacol; 2013 Sep; 715(1-3):96-104. PubMed ID: 23791609
[TBL] [Abstract][Full Text] [Related]
10. RGS18 acts as a negative regulator of osteoclastogenesis by modulating the acid-sensing OGR1/NFAT signaling pathway.
Iwai K; Koike M; Ohshima S; Miyatake K; Uchiyama Y; Saeki Y; Ishii M
J Bone Miner Res; 2007 Oct; 22(10):1612-20. PubMed ID: 17576169
[TBL] [Abstract][Full Text] [Related]
11. Kalkitoxin Reduces Osteoclast Formation and Resorption and Protects against Inflammatory Bone Loss.
Li L; Yang M; Shrestha SK; Kim H; Gerwick WH; Soh Y
Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33669069
[TBL] [Abstract][Full Text] [Related]
12. CTRP3 acts as a negative regulator of osteoclastogenesis through AMPK-c-Fos-NFATc1 signaling in vitro and RANKL-induced calvarial bone destruction in vivo.
Kim JY; Min JY; Baek JM; Ahn SJ; Jun HY; Yoon KH; Choi MK; Lee MS; Oh J
Bone; 2015 Oct; 79():242-51. PubMed ID: 26103094
[TBL] [Abstract][Full Text] [Related]
13. Technetium-99 conjugated with methylene diphosphonate inhibits receptor activator of nuclear factor-κB ligand-induced osteoclastogenesis.
Gong W; Dou H; Liu X; Sun L; Hou Y
Clin Exp Pharmacol Physiol; 2012 Oct; 39(10):886-93. PubMed ID: 23013134
[TBL] [Abstract][Full Text] [Related]
14. TNF-induced osteoclastogenesis and inflammatory bone resorption are inhibited by transcription factor RBP-J.
Zhao B; Grimes SN; Li S; Hu X; Ivashkiv LB
J Exp Med; 2012 Feb; 209(2):319-34. PubMed ID: 22249448
[TBL] [Abstract][Full Text] [Related]
15. Trichostatin A inhibits osteoclastogenesis and bone resorption by suppressing the induction of c-Fos by RANKL.
Kim HN; Ha H; Lee JH; Jung K; Yang D; Woo KM; Lee ZH
Eur J Pharmacol; 2009 Nov; 623(1-3):22-9. PubMed ID: 19766111
[TBL] [Abstract][Full Text] [Related]
16. miR-128 plays a critical role in murine osteoclastogenesis and estrogen deficiency-induced bone loss.
Shen G; Ren H; Shang Q; Zhang Z; Zhao W; Yu X; Tang J; Yang Z; Liang D; Jiang X
Theranostics; 2020; 10(10):4334-4348. PubMed ID: 32292498
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of osteoclastogenic differentiation by Ikarisoside A in RAW 264.7 cells via JNK and NF-kappaB signaling pathways.
Choi HJ; Park YR; Nepal M; Choi BY; Cho NP; Choi SH; Heo SR; Kim HS; Yang MS; Soh Y
Eur J Pharmacol; 2010 Jun; 636(1-3):28-35. PubMed ID: 20353769
[TBL] [Abstract][Full Text] [Related]
18. Diarylheptanoid from Curcuma comosa Roxb. suppresses RANKL-induced osteoclast differentiation by decreasing NFATc1 and c-Fos expression via MAPK pathway.
Chawalitpong S; Sornkaew N; Suksamrarn A; Palaga T
Eur J Pharmacol; 2016 Oct; 788():351-359. PubMed ID: 27523282
[TBL] [Abstract][Full Text] [Related]
19. RARγ is a negative regulator of osteoclastogenesis.
Green AC; Poulton IJ; Vrahnas C; Häusler KD; Walkley CR; Wu JY; Martin TJ; Gillespie MT; Chandraratna RA; Quinn JM; Sims NA; Purton LE
J Steroid Biochem Mol Biol; 2015 Jun; 150():46-53. PubMed ID: 25800721
[TBL] [Abstract][Full Text] [Related]
20. Microtubule actin crosslinking factor 1 (MACF1) knockdown inhibits RANKL-induced osteoclastogenesis via Akt/GSK3β/NFATc1 signalling pathway.
Lin X; Xiao Y; Chen Z; Ma J; Qiu W; Zhang K; Xu F; Dang K; Qian A
Mol Cell Endocrinol; 2019 Aug; 494():110494. PubMed ID: 31260729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
